[
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of June 22",
    "summary": "Dividend Champion, Contender, And Challenger Highlights: Week Of June 22",
    "url": "https://finnhub.io/api/news?id=5bd5c0a319f0463642d9a2cb71e7a26501a12df8b50c144dfab4d05bf0d13fee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750461169,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of June 22",
      "id": 135446856,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5bd5c0a319f0463642d9a2cb71e7a26501a12df8b50c144dfab4d05bf0d13fee"
    }
  },
  {
    "ts": null,
    "headline": "The FDA Shake-Up Continues, And Could Impact Genetic Medicines",
    "summary": "The FDA Shake-Up Continues, And Could Impact Genetic Medicines",
    "url": "https://finnhub.io/api/news?id=f3d5f1dae635b26abafe46bb7a19898f784935aaffda7af5ec3ce81db2d4b01e",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750435717,
      "headline": "The FDA Shake-Up Continues, And Could Impact Genetic Medicines",
      "id": 135478495,
      "image": "",
      "related": "GILD",
      "source": "DowJones",
      "summary": "The FDA Shake-Up Continues, And Could Impact Genetic Medicines",
      "url": "https://finnhub.io/api/news?id=f3d5f1dae635b26abafe46bb7a19898f784935aaffda7af5ec3ce81db2d4b01e"
    }
  },
  {
    "ts": null,
    "headline": "BMO says lenacapavir approval for prevention a ‘major win’ for Gilead",
    "summary": "Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its pre-exposure prophylaxis business. A clean label, strong clinical data, and a convenient twice yearly dosing regimen, in line with patient physician visits, should drive strong commercial adoption for Yeztugo, says the analyst, who has an Outperform rating and $120 price target on Gilead shares. Publishe",
    "url": "https://finnhub.io/api/news?id=a89fb2db0b75ad31657fcf06cb366978f437ea349f0313ba60ead0e8b38b1c1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750421126,
      "headline": "BMO says lenacapavir approval for prevention a ‘major win’ for Gilead",
      "id": 135424384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its pre-exposure prophylaxis business. A clean label, strong clinical data, and a convenient twice yearly dosing regimen, in line with patient physician visits, should drive strong commercial adoption for Yeztugo, says the analyst, who has an Outperform rating and $120 price target on Gilead shares. Publishe",
      "url": "https://finnhub.io/api/news?id=a89fb2db0b75ad31657fcf06cb366978f437ea349f0313ba60ead0e8b38b1c1e"
    }
  }
]